Thymosin Alpha-1 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Thymosin Alpha-1 supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025008

Key analytical results include:

• Assay Content: 10.13 mg
• Identification – Retention Time: 0.992
• Identification – Spectrum: 986
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Thymosin Alpha-1 is a synthetic peptide research compound frequently studied in controlled laboratory environments investigating immune signalling pathways and cellular regulatory mechanisms.

The peptide is a synthetic analogue derived from thymic peptides that are associated with immune system signalling and regulatory processes.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, Thymosin Alpha-1 has become a widely referenced compound in experimental immunological research models.

Compound Overview

Thymosin Alpha-1 is a synthetic peptide analogue originally derived from naturally occurring thymic peptides involved in immune system signalling.

The thymus plays an important role in immune cell maturation and regulation, and thymic peptides have been widely investigated for their role in cellular immune communication.

Research involving Thymosin Alpha-1 commonly focuses on peptide-mediated immune signalling pathways and cellular regulatory mechanisms.

Due to its well-defined molecular structure and biological relevance, the peptide is frequently used in laboratory research examining immune signalling networks and peptide interaction pathways.

Historical Background and Scientific Context

Scientific interest in thymic peptides began during the mid-twentieth century when researchers first identified the thymus as a critical organ involved in immune system development.

During the 1960s and 1970s, scientists began isolating and characterising peptides produced by the thymus that were involved in immune cell signalling.

Thymosin Alpha-1 emerged as one of the peptides studied for its involvement in immune regulatory pathways.

Synthetic versions of this peptide were subsequently developed to allow researchers to investigate immune signalling processes in controlled laboratory environments.

Mechanistic Focus in Research

Within experimental laboratory settings, Thymosin Alpha-1 is often studied in relation to immune regulatory pathways and peptide-mediated cellular signalling systems.

Research investigations commonly explore the compound in experimental models examining:

• Immune signalling pathways
• T-cell related regulatory mechanisms
• Cellular immune communication networks
• Peptide-mediated signalling pathways
• Immune regulatory enzyme systems
• Comparative peptide signalling research
• Cellular defence response modelling

These experimental models allow scientists to investigate molecular signalling processes involved in immune system regulation and cellular communication.

Research Applications

In controlled research environments, Thymosin Alpha-1 may be utilised in experimental models designed to explore immune signalling systems and peptide-mediated cellular regulation.

Examples of research applications include:

• Immune signalling pathway investigation
• Cell communication research
• Peptide signalling studies
• Comparative immunological compound evaluation
• Intracellular signalling network modelling
• Regulatory peptide interaction research
• Controlled in vitro immune system studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Purity above 99.8% with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin level below 0.001 EU per mg
• Batch GF082025008 – Published September 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.